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Introduction. The small renal masses (SRMs) have increased over the past two decades due to more liberal use of imaging
techniques. SRMs have allowed discussions regarding their prognostic, diagnosis, and therapeutic approach. Materials and
methods. Clinical presentation, incidental diagnosis, and prognosis factors of SRMs are discussed in this review. Results. SRMs
are deﬁned as lesions less than 4cm in diameter. SRM could be benign, and most malignant SMRs are low stage and low grade.
Clinical symptoms like hematuria are very rare, being diagnosed by chance (incidental) in most cases. Size, stage, and grade are
still the most consistent prognosis factors in (RCC). An enhanced contrast SRM that grows during active surveillance is clearly
malignant, and its aggressive potential increases in those greater than 3cm. Clear cell carcinoma is the most frequent cellular type
of malign SRM. Conclusions. Only some SRMs are benign. The great majority of malign SRMs have good prognosis (low stage
and grade, no metastasis) with open or laparoscopic surgical treatment (nephron sparing techniques). Active surveillance is an
accepted attitude in selected cases.
Copyright © 2008 F. M. S´ anchez-Mart´ ın et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The incidence of renal cell carcinoma (RCC) has increased
over the past two decades reﬂecting earlier diagnosis at an
earlier stage, largely due to more liberal use of radiological
imaging techniques [1], introducing concepts as “incidental”
or “small renal masses” (SRMs). SRM could be deﬁned
as those renal masses lower than 4cm in diameter [2–4],
accounting for 48–66% of RCC diagnosis [5]. Actually, 79–
84% of SRM are detected before genitourinary symptoms
are present [6–8] (size is smaller than symptomatic cancer
classifying it as local stage with a better prognosis) [9].
Although mean tumor size has decreased in the last years,
several studies indicate that this variable is one of the
most important prognosis factors for RCC, and it has also
contributed to the last modiﬁcations of RCC staging and
treatment [10, 11].
Yearsago,whenmostRCCweresymptomatic,hematuria
was the main symptom, so asymptomatic tumors were
diagnosed later or not diagnosed. Before widespread use
of imaging techniques, 67–74% of RCC remained unde-
tected until death (autopsies), and only 8.9–20.0% of these
undiagnosed RCC were responsible for the patient’s death
[5]. These data support the fact that some RCC have a
favorable evolution and support active surveillance in select
cases. Natural history of SRM has not been historically well
established because most masses were surgically removed
soon after diagnosis.
2. DEFINITIONS AND GENERAL CONCEPTS
A renal mass discovered by routine ultrasound, CT or MR
indicated for other pathology, could be named incidental.
A signiﬁcant number of SRMs are incidentally diagnosed
[2, 12]. Renal masses (benign and malign) can be considered
incidental if they are diagnosed in the absence of symptoms
or signs. “Incidentaloma” or “incidental” masses related
to other organs such as adrenal, pituitary, thyroid and
parathyroid, as well as the liver are published. Mirilas
and Skandalakis questioned the scientiﬁc justiﬁcation for2 Advances in Urology
this neologism and suggested that should be replaced by
“incidentally found” [13]. Narrow relation of “incidental”
and“smallmasses”areconsideredinsomepapers[2,14–16].
A possible confusion factor may be that tumors classiﬁed as
“incidental” show symptoms not directly attributable to the
renal mass, thus not detected by the urologist [5].
Small renal masses include all solid or complex cystic
lesions lower than 4cm. Among them, diﬀerent benign
tumors are found in a 12.8 to 17.3% of cases [17–19] includ-
ing oncocytoma in 53%, angiomyolipoma in 22%, atypical
cyst in 10%, and diﬀerent benign lesions as leiomyoma,
xanthogranulomatous pyelonephritis, and focal infarction in
13% [17].
Incidental renal tumors have a mean size of 3.7cm
(median 3, range 0.8 to 12) [7]. Nevertheless, tumors
greater than 4cm could be incidental. Incidental diagnosis
is performed in the 82.4%, 78.9%, and 56.7% of the 1–4cm,
4–6cm and greater than 6cm renal masses, respectively [5].
If a cut-oﬀ should be made, most cases of RCC lower than
7cm are incidentally discovered, while tumors greater than
7cm are mainly symptomatic but, as mentioned previously,
t h i sc a n n o tb et a k e na sar u l e[ 7].
3. SYMPTOMS
The main symptom of RCC is hematuria (35%–60%)
[20–22] but SRMs are often asymptomatic (incidental).
Classical manifestations of RCC such as fever or jaundice are
extremely rare in front of an SRM. In a study of 349 SRM’s,
microhematuria was reported in only 8 cases. Prognostic
of those RCC diagnosed by hematuria is worse than those
incidentally diagnosed [23]. Stage I lesions were observed in
62.1% of patients with incidental RCC renal cell carcinoma
and just in 23% with symptomatic RCC [6]. Among the
diﬀerent entities causing the incidental diagnosis of an SRM,
many have been considered; evaluation for other malignancy
(17.7%), gastrointestinal symptoms including nonspeciﬁc
abdominal pain (16%), evaluation of medical renal disease
(6.6%), hypertension (4%), back pain (5.1%), cirrhosis
(1.4%), nephrolithiasis (1.4%), diverticulitis (1.4%), lung
lesion (1.1%), increased liver enzymes (1.1%), trauma
(0.8%), screening CT (0.8%), urinary tract infection (0.8%),
chestpain(0.8%),aorticaneurysmevaluation(0.8%),cough
(0.5%), shortness of breath (0.5%), Crohn’s disease (0.5%),
bronchocele(0.5%),andanemia(0.5%).Nodiﬀerenceswere
found among incidental or symptomatic RCC according to
age, sex, and laterality [15].
Laboratory ﬁndings have a signiﬁcant impact on the
patients with organ-conﬁned RCC prognosis. Although,
neoplasic condition reﬂects an increased invasive potential,
characterized by overexpression of substances involved in
cell proliferation as matrix metalloproteinases [24]; how-
ever, inﬂammatory markers like erythrocyte sedimentation
rate greater than 30mm/hour, hemoglobin levels less than
10gm/dL (female) or 12gm/dL (male), and increased alka-
line phosphatase are negative prognosis elements [22].
Some demographic data may help to presume the matter
ofSRM:RCCisunusualinyoungpatients;angiomyolipomas
and multilocular cystic nephromas are more common in
women [25].
4. PROGNOSIS FACTORS
Age is not a signiﬁcant factor on survival in patients with
incidental RCC [26], so it is probably not a prognosis factor
for SRM [5]. However, as the patient ages, the SMR stage is
higher; so the incidence of SRM ﬁnally staged as pT3 tumors
inyoungerthan45years,45–75years,andolderthan75years
is 2.3%, 6.9%, and 14.3%, respectively [17]. The probability
of developing metastases, with 12 years follow-up, is greater
in men [27].
5. BENIGN TUMOR FREQUENCY
Lee et al. published 230 cases of SRM (lower than 4cm),
88%malignantand12%benign(oncocytoma)[6].DeRoche
et al. described that SRMs are nonneoplasic entities. Benign
neoplasms and low-and high-grade carcinoma accounted
for 1.6%, 18.0%, 49.0%, and 31.4%, respectively [8]. The
percentage of malignancies increases from 72.1% in masses
lower than 2cm to 93.7% in tumors greater than 7cm [7].
In conclusion, if the tumor is greater in dimensions, the
possibility of being benign is lower; so tumors lower than
1, 2, 3, and 4cm were benign in 46.3, 22.4, 22, and 19.9%,
respectively [18].
6. SIZE AND STAGE
In a study from Schlomer et al., global mean renal tumor
size decreased by 32% and pT1 tumors increased from 4%
to 22% (1989–1998). For every cm increase in size, the
odds ratio of malignancy increased 17–39% [7, 18]. Mean
tumor size for benign tumors was 4.2cm (median 3.3, range
0.2–25) compared to 6.3cm (median 5.5, range 0.1–24) for
malignant tumors. Median clinical diameter was 2.93cm
(range 0.8 to 4.0) in RCC lower than 4cm. RCC mean
size was 4.6cm (range 0.8–21) and benign masses mean
size 2.8cm (range 0.8–9.5) [5]. Incidental RCC mean size
was 3.7cm (median 3, range 0.8–12) and symptomatic RCC
mean size was 6.2cm [7]. In pathological stage, 51.33% and
27.3% were pT1, 25.6% and 27.3% pT2, 10.9% and 23.8%
pT3a, 10.9% and 16.6% pT3b, 1.2% and 2.3% pT3c, and
0% and 2.3% pT4 in incidental and symptomatic RCC,
respectively.
Puppoetal.reported94patientswithresectedRCC(size:
1.1–4.5cm), describing that pathological stage was pT1a in
92.5%, pT1b in 4.2%, and pT3a in 3.1% [28], similar to
Pahernik et al. that reports pT1a in 84.5%, pT1b in 8%, and
pT3 in7.5%(organconﬁnedin92.5%) and ≥pT3wasfound
in 3.0%, 5.1%, and 12.1% of the patients when analyzed by
t u m o rs i z e2 ,3 ,a n d4c m ,r e s p e c t i v e l y[ 17]. A total of 25%
of SRM doubled in volume within 12 months, 34% reached
4cm and experienced rapid doubling time [5].
Kunkle et al. found synchronous metastatic disease
increased by 22% with eachcm increase in tumor size, by
50% for each increase of 2cm, and doubled for each 3.5cm
increase in primary tumor size [11].F. M. S´ anchez-Mart´ ın et al. 3
In other manuscript, incidental RCC had lower stages
compared to symptomatic RCC [15]. Between T1a and T1b
lesions, there was no signiﬁcant diﬀerence in the rate of
malignancy and high-grade malignancy regarding incidental
or symptomatic presentation. The diﬀerent percentage of T2
malignant tumors between incidental (90.9%) and symp-
tomatic tumors was neither signiﬁcant [5]. Understaging
for pT3 tumors lower than 3cm was 7.5% [17]. Cystic
component appears in 24.1% of renal masses lower than
4cm, being 57.1% in Bosniak type III and the rest in Bosniak
type IV [5].
Volpe et al. showed no diﬀerences between the average
growth rate for solid SRM (0.11cm per year) and cystic
masses (0.09cm per year) [5]. Multifocality was present in
5.3–12% in small RCC [7, 8]. The rate of multifocality
was 2.0%, 5.1%, and 7.05% in tumors of 2, 3, and 4cm,
respectively [17].
7. GRADE
Ninety percent of tumors lower than 1cm were low-grade
compared to only 37.9% of tumors ≥7cm [18]. Grade 3
was found in 7.1%, 9.0%, and 14.0% of the patients in the
2, 3, and 4cm groups, respectively and just 10.6% of small
RCC were grade 3 [17]. Tumor grade increase as tumor
size increase from 2 to 4cm. Grade 1 was 31.3% for 2cm,
27.4% for 3cm, and 18.1% for 4cm tumors; and grade 3 was
7.1% for 2cm, 9% for 3cm, and 14% for 4cm tumors [17].
Urinary tract invasion, reported in some low-grade tumors,
is a negative prognostic factor [29]. However, 45% of T2
incidental malignancies were high grade compared to 78.8%
of T2 symptomatic malignancies [5]. Tumor grade increased
according to size in clear cell, papillary, and chromophobe
tumors. In high-grade carcinomas, 65% of the tumors had a
1-year volume doubling time.
8. CELLULAR TYPE
Clear cell is the most frequent cellular type regardless of
tumor size [7]. Among SRM, Frank et al. showed that
percentage of clear cell cellular type increased according to
size: 59.9, 70.2, and 72% in lower than 2, 3, and 4cm,
respectively [18]. Cellular type for small RCC was 78%
clear cell carcinoma, 15.3% papillary carcinoma, and 7%
chromophobe carcinoma [17].
Volpe et al. showed that papillary RCC incidence is more
frequent in 2cm tumors than in 3 and 4cm tumors (24%,
13.2%, and 13.5%, resp.) [17]; data not refuted by other
authors [5]. Papillary cell type is more frequent than clear
cell in tumors lower than 1cm [18].
9. METASTASES
Metastases at diagnosis were found in 3.0%, 2.6%, and
6.0% of the patients with 2, 3, and 4cm renal tumors,
respectively[17].Furthermore,lymphnodespreadwas4.8%
and15%,metastasiswas9.2%and26%,andlocalrecurrence
was 1.2% and 8.3%, among incidental and symptomatic
RCC, respectively [15]. With active surveillance, enhancing
lesions with zero median growth rates did not progress to
metastatic disease, and only 1.4% of patients with 0.31cm
yearly median growth rate progressed to metastatic disease
[7]. Chawla et al. showed RCC mean growth rate of 0.40cm
yearly (median 0.35, range 0.42 to 1.6) [30].
Median tumor size for patients presented with patho-
logically conﬁrmed synchronous metastatic disease was
signiﬁcantly greater than for those presenting with localized
disease, 8.0cm (range 2.2 to 20.0) and 4.5cm (range 0.3
to 17.5), respectively. Tumors of 3.0cm or smaller had
synchronous metastasis in just 4.5% of the cases [31].
10. SURVIVAL
A total of 548 patients with small RCC were analyzed by
Pahernik et al.: 22 (4%) had metastasis, 9 died by cancer in a
m e a nt i m eo f1 . 9y e a r s( r a n g e0 . 7t o3 . 4 )a f t e rd i a g n o s i s[ 17].
D’allOglio et al. observed a mean overall survival of 91% in
patients with T1a tumors and up to 78.7% survival after 10
years of local treatment [15].
Several groups have developed predictive models to
construct prognosis algorithms in order to facilitate follow-
up and to indentify progression risk. Raj et al. present a
predictive model that includes gender, symptoms, radiolog-
ical ﬁndings, and size as preoperative prognostic factors; in
order to establish a chance of being cancer-free 12 years after
surgery (Figure 1). In case of SRM, it could not be useful
to decide surveillance or active treatment. For example, a
womanwitha3cmincidentalmalignSRMhasa96%chance
of being cancer-free 12 years after surgery. In contrast, a
man with a 4cm symptomatic (local signs) malign SRM and
positive TC showing enlarged lymph nodes has 60% chance
of being cancer-free 12 years after surgery [27].
Classically, better prognosis has been assigned to inci-
dental diagnosis, papillary or chromophobe pathology, small
size, and early stage [32]. Presence of necrosis and vascular
invasion is useful in a speciﬁc algorithm looked toward clear
cell renal tumor [33].
Table 1 resumes the main prognosis factors useful on
SRM.
11. TREATMENT AS PROGNOSIS FACTOR
Size is a signiﬁcant factor in the decision to perform NSS:
tumors sized 2cm (81%), 3cm (73%), and 4cm (44%)
cm could be treated by means of NSS. This treatment is
technicallyeasierinincidentalthannotincidentalRCC(76%
versus 24%) [15]. Local excision is a safe treatment for small
RCC, even in extreme cases such as living donor kidney
with a 5 × 5mmRCCfoundonitssurface[34]. In patients
with RCC lower 4cm, who underwent partial or radical
nephrectomy 14% and 10% died during follow-up (cancer-
speciﬁc death occurred in 3% in both approaches). Disease
speciﬁc survival rate at 3 and 5 years is 95 and 97% in partial
and radical nephrectomy, respectively [6].
When active surveillance is applied to 2cm mean
size contrast-enhancing renal masses, no diﬀerences were
reported about age, sex, initial size, and solid versus cystic
radiologic appearance. A signiﬁcant diﬀerent frequency4 Advances in Urology
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Figure 1: Preoperatory prognosis RCC nomogram [27].
Table 1: Small RCC prognosis factors.
Better prognosis Worse prognostic
Incidental Symptoms
Small size <3cm Size > 3cm
T1 T2 and >
Low grade High grade
No upper tract invasion Upper tract invasion
No lymph nodes Necrosis
No necrosis Lymph nodes
No vascular invasion Vascular invasion
Negative biological markers Positive biological markers
Papillary or chromophobe
pathology (¿) Sarcomatoid component
Zero median grown rate Grown rate > 0.31cm yearly
Option to NSS No option to NSS
of surgery was found among tumors with 0 or 0.31cm
mean yearly growth rate of 17% and 51%, respectively [7].
However, 33% of SRM under active surveillance showed
zero or negative radiologic growth [7]. The probability to
develop metastasis in masses lower than 3cm managed by
active surveillance was only 2% [14]. Prior and during
follow-up, renal tumor biopsies are recommended. As a
general rule, biopsy may be indicated in masses that have
features of oncocytoma in poor surgical candidates. For
patients who have a surgical contraindication or reject
surgery, alternative ablation techniques can be proposed
(cryoablation, radiofrequency) [35].
For Kassouf et al., 20.8% of renal masses showed tumor
growth during the surveillance period (mean 31.6 months),
but neither of them developed metastasis. Patients receiving
surgical treatment after surveillance did not modify their
prognostic [16]. Hereditary renal tumors may have a more
aggressive natural history, and thus surveillance should be
made with caution. Meta-analysis of Kunkle et al. observed
no statistical diﬀerences in the incidence of SRM progression
regardless excision, ablation, or active surveillance [2].
12. CONCLUSIONS
SRMs are those smaller than 4cm, often incidentally diag-
nosed. Clinical symptoms, like hematuria, are rare, but
confer worse prognosis. Size, stage, and grade are still the
most consistent prognostic factors in RCC. It is important
to keep in mind that SRM could be benign tumors, mainly
oncocytoma.MostmalignSMRsarelowstageandlowgrade,
without metastatic spread if diameter is below 2-3cm. Clear
cell carcinoma is the most frequent cellular type of malign
SRM. Papillary tumors are more frequent when SRM size is
lessthan1cm,havingabetterprognosis.Aggressivepotential
of small RCC could increase in tumors greater than 3cm,
so it is suggested that the threshold for selecting patients
(old age, high-risk, solitary kidney, reject surgery) for a
surveillance strategy should be set well below a tumor size
of 3cm. In active surveillance, the size increase of an SRM is
a strong indicator of malignancy; helping to decide a surgical
treatment.
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